WORCESTER, Mass., June 4, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that data in respect of two of its products will be presented at the American Diabetes Association's (ADA's) 69th Annual Scientific Sessions being held in New Orleans from June 5 to 9. The annual meeting of the ADA (www.diabetes.org) is one of the largest scientific meetings for endocrinologists and other health care professionals involved in diabetes research and diabetes care.
As part of the session on New Concepts on Insulin Delivery Applications, independent clinician Professor Paolo Pozzilli, Head of the Department of Diabetes and Endocrinology at University Campus Bio-Medico, Rome, Italy, will present his abstract (co-authored with Andrea Palermo, Nicola Napoli, Flavia Costanza, Giusy Beretta and Silvia Manfrini) entitled Buccal Spray Insulin for the Management of Post-Prandial Hyperglycaemia in Subjects with Impaired Glucose Tolerance on June 7, 2009 at 5:30 p.m. CDT at the Morial Convention Center in New Orleans, Louisiana. The abstract provides positive safety and efficacy data in respect of a phase 2 clinical trial of Generex Oral-lyn(tm), the Company's proprietary oral insulin spray product, in patients with Impaired Glucose Tolerance(blood glucose 140 to199 after meals).
In addition, an abstract entitled A Novel Tool to Control Hypoglycaemia and Improve HbA1c in Very Young Children with Type 1 Diabetes, which features Glucose RapidSpray(tm), the Company's proprietary glucose buccal spray product, will be a poster presentation at the 2009 ADA scientific sessions. Hypoglycemia or low blood sugar is often an inhibitor of aggressive insulin treatment and compromises quality of life. The abstract is co-authored by Ekaterina Pronina, Helen Petraikina, Michael Antisiferov and Olga Duchareva of Morozovskaya Children City Clinical Hospital, Department of Endocrinology, Moscow, Russian Federation, and Professor Paolo Pozzilli and Chiara Guglielmi of the Department of Diabetes and Endocrinology, University Campus Bio-Medico, Rome, Italy.
"We are pleased that the scientific community continues to recognize the significance of our work on buccal drug delivery technologies for the treatment of metabolic diseases," said Anna Gluskin, Generex's President & Chief Executive Officer. "Professor Pozzilli's podium presentation will highlight the potential broad-spectrum application of our oral insulin in the metabolic diseases market."
The Company believes that Generex Oral-lyn(tm) will offer a safe, simple, fast, effective and pain-free alternative to meal time insulin injections which will improve patient compliance with therapeutic regimes thereby delaying the progress of diabetes and the onset of its myriad complications.
Glucose RapidSpray(tm) is an innovative alternative for people who want additional glucose in their diet. Glucose RapidSpray(tm) delivers a fat-free, low-calorie glucose formulation developed using the Company's proprietary buccal drug delivery technologies. Glucose RapidSpray(tm) delivers glucose directly into the buccal cavity and is simple to carry and use.
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in India and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at http://www.generex.com.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.